These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9419170)

  • 1. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Griffiths PD; Feinberg JE; Fry J; Sabin C; Dix L; Gor D; Ansari A; Emery VC
    J Infect Dis; 1998 Jan; 177(1):57-64. PubMed ID: 9419170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
    J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
    J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The status of CMV viral load testing.
    Feinberg J
    AIDS Clin Care; 1996 Oct; 8(10):81. PubMed ID: 11363986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.
    Chanouzas D; Dyall L; Nightingale P; Ferro C; Moss P; Morgan MD; Harper L
    Trials; 2016 Jul; 17(1):338. PubMed ID: 27450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose valaciclovir linked to problems.
    TreatmentUpdate; 1998 Mar; 10(1):4-6. PubMed ID: 11365432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from the natural history of cytomegalovirus.
    Bowen EF; Griffiths PD; Davey CC; Emery VC; Johnson MA
    AIDS; 1996 Nov; 10 Suppl 1():S37-41. PubMed ID: 8970675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.
    Nokta MA; Holland F; De Gruttola V; Emery VC; Jacobson MA; Griffiths P; Pollard RB; Feinberg JE;
    J Infect Dis; 2002 Jun; 185(12):1717-22. PubMed ID: 12085316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
    Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
    Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cytomegalovirus anterior uveitis with oral valaciclovir.
    Sira M; Murray PI
    Ocul Immunol Inflamm; 2007; 15(1):31-2. PubMed ID: 17365804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women.
    Roxby AC; Atkinson C; Asbjörnsdóttir K; Farquhar C; Kiarie JN; Drake AL; Wald A; Boeckh M; Richardson B; Emery V; John-Stewart G; Slyker JA
    PLoS One; 2014; 9(2):e87855. PubMed ID: 24504006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
    Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
    Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunistic infection highlights from the 35th ICAAC.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):8, 10-2. PubMed ID: 11362919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).
    Bell WR; Chulay JD; Feinberg JE
    Medicine (Baltimore); 1997 Sep; 76(5):369-80. PubMed ID: 9352739
    [No Abstract]   [Full Text] [Related]  

  • 19. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
    Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
    HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganciclovir studies leave clinicians confused.
    AIDS Alert; 1995 Nov; 10(11):139-41. PubMed ID: 11362926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.